Influence du traitement sur l’évolution à long terme de l’hépatite chronique B

Lau, 2005, Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B, N Engl J Med, 352, 2682, 10.1056/NEJMoa043470 Buster, 2009, Early HBeAg loss during peginterferon alpha-2b therapy predicts HBsAg loss: results of a long-term follow-up study in chronic hepatitis B patients, Am J Gastroenterol, 104, 2449, 10.1038/ajg.2009.371 Marcellin, 2004, Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B, N Engl J Med, 351, 1206, 10.1056/NEJMoa040431 Marcellin, 2009, Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a, Gastroenterol, 136, 2169, 10.1053/j.gastro.2009.03.006 Buster, 2009, Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa, Gastroenterol, 137, 2002, 10.1053/j.gastro.2009.08.061 Poynard, 2009, Impact of interferon-alpha treatment on liver fibrosis in patients with chronic hepatitis B: an overview of published trials, Gastroenterol Clin Biol, 33, 916, 10.1016/j.gcb.2009.06.006 Chang, 2010, Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B, Hepatol, 51, 422, 10.1002/hep.23327 Marcellin, 2008, Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B, N Engl J Med, 359, 2442, 10.1056/NEJMoa0802878 van Bömmel, 2010, Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues, Hepatol, 51, 73, 10.1002/hep.23246 Marcellin, 2009, Three years of tenofovir disoproxil fumarate (TDF) treatment in HBEAG-negative patients with chronic hepatits B (study 102); preliminary analysis, Hepatology, 50, 140A Heathcote, 2009, Three years of tenofovir disoproxil (TDF) treatment in HBEAG-positive patients (HBEAG+) with chronic heptatitis B (study 103), preliminary analysis, Hepatology, 50, 140A Lai, 2006, Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B, N Engl J Med, 354, 1011, 10.1056/NEJMoa051287 Hadziyannis, 2005, Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B, N Engl J Med, 352, 2673, 10.1056/NEJMoa042957 Hadziyannis, 2006, Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years, Gastroenterol, 131, 1743, 10.1053/j.gastro.2006.09.020 Marcellin, 2008, Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B, Hepatol, 48, 750, 10.1002/hep.22414 Liaw, 2008, Long-term entecavir therapy results in reversal of fibrosis/cirrhosis and continued histologic improvement in patients with HBEAG (+) and (-) chronic hepatitis B: results from studies ETV-022, -027 and -901, Hepatol, 40, 706A